Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05708872 Recruiting - Pain, Postoperative Clinical Trials

The Effect of Methods of Self-regulation of Mental State on Pain Perception in the Postoperative Period in Colon Cancer Patients

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

In this study, it will be investigated whether the methods of self-regulation of mental state have an effect on postoperative pain perception in colon cancer patients.

NCT ID: NCT05707910 Recruiting - Malignant Tumor Clinical Trials

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

Start date: February 10, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety of therapeutic immunological agent against EBV-positive advanced malignancies, examining the incidence, type of occurrence, and severity of adverse events in relation to the agent tested, and initially exploring the effectiveness of the immunological agent.

NCT ID: NCT05707676 Recruiting - Solid Tumor Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors(MEETCD8-001)

MEETCD8-001
Start date: November 30, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors

NCT ID: NCT05707325 Recruiting - Cancer Clinical Trials

Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies

Reboot-101
Start date: October 31, 2022
Phase: Phase 1
Study type: Interventional

This phase studies the engineered red blood cells with PD-1 inhibitor pembrolizumab(WTX212), the natural biological metabolic function of red blood cells can make the carried pembrolizumab directionally distributed in the spleen tissue and activitate T cells, suggesting that this product may solve the problem that PD-1 treatment failure.

NCT ID: NCT05706207 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of HB0030 Injection in Patients With Advanced Solid Tumors

Start date: December 21, 2021
Phase: Phase 1
Study type: Interventional

This is a phase Ia single-center, open-label, dose escalation study.The objectives of this study are to evaluate the safety, toxicity, tolerability, pharmacokinetics/pharmacodynamics(PK/PD), immunogenicity, biomarkers, and antitumor activity of HB0030 in advanced solid tumor subjects.

NCT ID: NCT05704621 Recruiting - Ovarian Cancer Clinical Trials

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

SOCCER-P
Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.

NCT ID: NCT05703243 Recruiting - Clinical trials for Stage IV Solid Tumors

Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")

DINOSAur II
Start date: February 1, 2023
Phase:
Study type: Observational [Patient Registry]

To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive l i q u i d molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

NCT ID: NCT05701709 Recruiting - Clinical trials for Advanced Solid Tumors

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

Start date: April 6, 2023
Phase: Phase 1
Study type: Interventional

The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II study.

NCT ID: NCT05701527 Recruiting - Clinical trials for Advanced Solid Tumours

A Study of EBC-129 in Advanced Solid Tumours

Start date: April 28, 2023
Phase: Phase 1
Study type: Interventional

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

NCT ID: NCT05701462 Recruiting - Pleural Thickening Clinical Trials

Role of B Mode and Color Doppler Sonography in Differentiation Between Pleural Neoplasm and Inflammatory Pleural Thickening in Correlation With CT Findings

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

pleura is a serous membrane, it consist of parietal pleura and visceral pleura. pleural thickening is any form of thickening involving the pleura more than 3 mm. there is malignant thickening : methoselioma, metastasis and non malignant thickening. trans thoracic USn is a reliable , safe and gold standard for studying pleura.